249 related articles for article (PubMed ID: 32189461)
1. Impact of adjuvant chemotherapy on outcomes in appendiceal cancer.
Kolla BC; Petersen A; Chengappa M; Gummadi T; Ganesan C; Gaertner WB; Blaes A
Cancer Med; 2020 May; 9(10):3400-3406. PubMed ID: 32189461
[TBL] [Abstract][Full Text] [Related]
2. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms.
Choe JH; Overman MJ; Fournier KF; Royal RE; Ohinata A; Rafeeq S; Beaty K; Phillips JK; Wolff RA; Mansfield PF; Eng C
Ann Surg Oncol; 2015 Aug; 22(8):2578-84. PubMed ID: 25582740
[TBL] [Abstract][Full Text] [Related]
3. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
4. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin.
Munoz-Zuluaga CA; King MC; Ledakis P; Gushchin V; Sittig M; Nieroda C; Zambrano-Vera K; Sardi A
Eur J Surg Oncol; 2019 Sep; 45(9):1598-1606. PubMed ID: 31109821
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy for high-grade appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Baron E; Sardi A; King MC; Nikiforchin A; Lopez-Ramirez F; Nieroda C; Gushchin V; Ledakis P
Eur J Surg Oncol; 2023 Jan; 49(1):179-187. PubMed ID: 36253240
[TBL] [Abstract][Full Text] [Related]
6. Should We Be Doing Cytoreductive Surgery with HIPEC for Signet Ring Cell Appendiceal Adenocarcinoma? A Study from the US HIPEC Collaborative.
Levinsky NC; Morris MC; Wima K; Sussman JJ; Ahmad SA; Cloyd JM; Kimbrough C; Fournier K; Lee A; Dineen S; Dessureault S; Veerapong J; Baumgartner JM; Clarke C; Zaidi MY; Staley CA; Maithel SK; Leiting J; Grotz T; Lambert L; Hendrix RJ; Ronnekleiv-Kelly S; Pokrzywa C; Raoof M; Eng OS; Johnston FM; Greer J; Patel SH
J Gastrointest Surg; 2020 Jan; 24(1):155-164. PubMed ID: 31428960
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathological features and prognosis of primary appendiceal adenocarcinoma].
Liang JW; Wang Z; Zhou ZX; Zhang XM; Hu JJ; Zhao P
Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):616-9. PubMed ID: 23158998
[TBL] [Abstract][Full Text] [Related]
8. Impact of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal adenocarcinoma.
Flood MP; Roberts G; Mitchell C; Ramsay R; Michael M; Heriot AG; Kong JC
Asia Pac J Clin Oncol; 2024 Feb; 20(1):32-40. PubMed ID: 36880398
[TBL] [Abstract][Full Text] [Related]
9. Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery.
Uemura M; Qiao W; Fournier K; Morris J; Mansfield P; Eng C; Royal RE; Wolff RA; Raghav K; Mann GN; Overman MJ
BMC Cancer; 2017 May; 17(1):331. PubMed ID: 28506255
[TBL] [Abstract][Full Text] [Related]
10. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit.
Bhutiani N; Grotz TE; Concors SJ; White MG; Helmink BA; Raghav KP; Taggart MW; Beaty KA; Royal RE; Overman MJ; Matamoros A; Scally CP; Rafeeq S; Mansfield PF; Fournier KF
Ann Surg Oncol; 2024 Jan; 31(1):614-621. PubMed ID: 37872456
[TBL] [Abstract][Full Text] [Related]
11. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
[TBL] [Abstract][Full Text] [Related]
12. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
[TBL] [Abstract][Full Text] [Related]
13. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base.
Asare EA; Compton CC; Hanna NN; Kosinski LA; Washington MK; Kakar S; Weiser MR; Overman MJ
Cancer; 2016 Jan; 122(2):213-21. PubMed ID: 26506400
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
[TBL] [Abstract][Full Text] [Related]
16. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641
[TBL] [Abstract][Full Text] [Related]
17. Comparing Survival Outcomes and Impact of EPIC in Patients Undergoing CRS/HIPEC for Mucinous Appendiceal Neoplasm.
Mercado M; Shamavonian R; Cheng E; Ahmadi N; Morris DL
Anticancer Res; 2023 Feb; 43(2):817-822. PubMed ID: 36697077
[TBL] [Abstract][Full Text] [Related]
18. Defining "Complete Cytoreduction" After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for the Histopathologic Spectrum of Appendiceal Carcinomatosis.
Munoz-Zuluaga CA; King MC; Diaz-Sarmiento VS; Studeman K; Sittig M; MacDonald R; Nieroda C; Zambrano-Vera K; Gushchin V; Sardi A
Ann Surg Oncol; 2020 Dec; 27(13):5026-5036. PubMed ID: 32705513
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection.
Grotz TE; Overman MJ; Eng C; Raghav KP; Royal RE; Mansfield PF; Mann GN; Robinson KA; Beaty KA; Rafeeq S; Matamoros A; Taggart MW; Fournier KF
Ann Surg Oncol; 2017 Sep; 24(9):2646-2654. PubMed ID: 28695394
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cyoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Garach NR; Kusamura S; Guaglio M; Bartolini V; Deraco M; Baratti D
Eur J Surg Oncol; 2021 May; 47(5):1132-1139. PubMed ID: 33280949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]